PGF and endometrial cancer: Since pre-clinical studies have proven the benefit of PlGF-targeting antibodies (11–13) and clinical studies have already shown the safety of these agents (27), the use of PlGF-targeting strategies in endometrial cancer, whether or not in combination with other treatment options, may be considered in the future.